Effect of D-penicillamine on lymphocyte subsets: correlation with clinical response in rheumatoid arthritis.

R. R. Singh, A. N. Malaviya, R. Malaviya, M. Sharma, R. Shandilya, Veena D Taneja, S. D. Khare, D. Beri, A. Kumar, N. K. Mehra

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We studied the effects of D-penicillamine (DP) on the clinical response, immunoinflammatory parameters and the lymphocyte subsets in 46 patients with rheumatoid arthritis (RA). Patients were evaluated before the start of the drug and then at 3 and 9 months during the follow up. 38 of 46 (82.6%) patients could continue DP treatment for over 9 months, while in 8 the drug was withdrawn due to adverse effects. Improvement in the various disease activity indices of more than 50% (responders) was seen in 25 of 38 (65.8%) patients. Responders showed a significant decrease in the serum IgA and IgM at 9 months, and in IgM only at 3 months. The serum levels of C3 and C4 did not show any significant change. Serum levels of C-reactive protein and rheumatoid factor (RF) showed a significant decrease at 3 and 9 months. A significant decrease in CD3+ and CD4+ lymphocytes along with a fall in CD4+/CD8+ lymphocyte ratio was also seen in responders at 3 and 9 months, compared to the baseline. Our results suggest that DP may have immunomodulatory action in RA.

Original languageEnglish (US)
Pages (from-to)201-204
Number of pages4
JournalThe Journal of the Association of Physicians of India
Volume42
Issue number3
StatePublished - Mar 1994
Externally publishedYes

Fingerprint

Penicillamine
Lymphocyte Subsets
Rheumatoid Arthritis
Immunoglobulin M
Serum
Lymphocytes
CD4-CD8 Ratio
Rheumatoid Factor
Pharmaceutical Preparations
C-Reactive Protein
Immunoglobulin A
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of D-penicillamine on lymphocyte subsets : correlation with clinical response in rheumatoid arthritis. / Singh, R. R.; Malaviya, A. N.; Malaviya, R.; Sharma, M.; Shandilya, R.; Taneja, Veena D; Khare, S. D.; Beri, D.; Kumar, A.; Mehra, N. K.

In: The Journal of the Association of Physicians of India, Vol. 42, No. 3, 03.1994, p. 201-204.

Research output: Contribution to journalArticle

Singh, RR, Malaviya, AN, Malaviya, R, Sharma, M, Shandilya, R, Taneja, VD, Khare, SD, Beri, D, Kumar, A & Mehra, NK 1994, 'Effect of D-penicillamine on lymphocyte subsets: correlation with clinical response in rheumatoid arthritis.', The Journal of the Association of Physicians of India, vol. 42, no. 3, pp. 201-204.
Singh, R. R. ; Malaviya, A. N. ; Malaviya, R. ; Sharma, M. ; Shandilya, R. ; Taneja, Veena D ; Khare, S. D. ; Beri, D. ; Kumar, A. ; Mehra, N. K. / Effect of D-penicillamine on lymphocyte subsets : correlation with clinical response in rheumatoid arthritis. In: The Journal of the Association of Physicians of India. 1994 ; Vol. 42, No. 3. pp. 201-204.
@article{fbbed785232d4eeb8c387e0b1243459f,
title = "Effect of D-penicillamine on lymphocyte subsets: correlation with clinical response in rheumatoid arthritis.",
abstract = "We studied the effects of D-penicillamine (DP) on the clinical response, immunoinflammatory parameters and the lymphocyte subsets in 46 patients with rheumatoid arthritis (RA). Patients were evaluated before the start of the drug and then at 3 and 9 months during the follow up. 38 of 46 (82.6{\%}) patients could continue DP treatment for over 9 months, while in 8 the drug was withdrawn due to adverse effects. Improvement in the various disease activity indices of more than 50{\%} (responders) was seen in 25 of 38 (65.8{\%}) patients. Responders showed a significant decrease in the serum IgA and IgM at 9 months, and in IgM only at 3 months. The serum levels of C3 and C4 did not show any significant change. Serum levels of C-reactive protein and rheumatoid factor (RF) showed a significant decrease at 3 and 9 months. A significant decrease in CD3+ and CD4+ lymphocytes along with a fall in CD4+/CD8+ lymphocyte ratio was also seen in responders at 3 and 9 months, compared to the baseline. Our results suggest that DP may have immunomodulatory action in RA.",
author = "Singh, {R. R.} and Malaviya, {A. N.} and R. Malaviya and M. Sharma and R. Shandilya and Taneja, {Veena D} and Khare, {S. D.} and D. Beri and A. Kumar and Mehra, {N. K.}",
year = "1994",
month = "3",
language = "English (US)",
volume = "42",
pages = "201--204",
journal = "Journal of Association of Physicians of India",
issn = "0004-5772",
publisher = "Journal of Association of Physicians of India",
number = "3",

}

TY - JOUR

T1 - Effect of D-penicillamine on lymphocyte subsets

T2 - correlation with clinical response in rheumatoid arthritis.

AU - Singh, R. R.

AU - Malaviya, A. N.

AU - Malaviya, R.

AU - Sharma, M.

AU - Shandilya, R.

AU - Taneja, Veena D

AU - Khare, S. D.

AU - Beri, D.

AU - Kumar, A.

AU - Mehra, N. K.

PY - 1994/3

Y1 - 1994/3

N2 - We studied the effects of D-penicillamine (DP) on the clinical response, immunoinflammatory parameters and the lymphocyte subsets in 46 patients with rheumatoid arthritis (RA). Patients were evaluated before the start of the drug and then at 3 and 9 months during the follow up. 38 of 46 (82.6%) patients could continue DP treatment for over 9 months, while in 8 the drug was withdrawn due to adverse effects. Improvement in the various disease activity indices of more than 50% (responders) was seen in 25 of 38 (65.8%) patients. Responders showed a significant decrease in the serum IgA and IgM at 9 months, and in IgM only at 3 months. The serum levels of C3 and C4 did not show any significant change. Serum levels of C-reactive protein and rheumatoid factor (RF) showed a significant decrease at 3 and 9 months. A significant decrease in CD3+ and CD4+ lymphocytes along with a fall in CD4+/CD8+ lymphocyte ratio was also seen in responders at 3 and 9 months, compared to the baseline. Our results suggest that DP may have immunomodulatory action in RA.

AB - We studied the effects of D-penicillamine (DP) on the clinical response, immunoinflammatory parameters and the lymphocyte subsets in 46 patients with rheumatoid arthritis (RA). Patients were evaluated before the start of the drug and then at 3 and 9 months during the follow up. 38 of 46 (82.6%) patients could continue DP treatment for over 9 months, while in 8 the drug was withdrawn due to adverse effects. Improvement in the various disease activity indices of more than 50% (responders) was seen in 25 of 38 (65.8%) patients. Responders showed a significant decrease in the serum IgA and IgM at 9 months, and in IgM only at 3 months. The serum levels of C3 and C4 did not show any significant change. Serum levels of C-reactive protein and rheumatoid factor (RF) showed a significant decrease at 3 and 9 months. A significant decrease in CD3+ and CD4+ lymphocytes along with a fall in CD4+/CD8+ lymphocyte ratio was also seen in responders at 3 and 9 months, compared to the baseline. Our results suggest that DP may have immunomodulatory action in RA.

UR - http://www.scopus.com/inward/record.url?scp=0028402432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028402432&partnerID=8YFLogxK

M3 - Article

C2 - 7860508

AN - SCOPUS:0028402432

VL - 42

SP - 201

EP - 204

JO - Journal of Association of Physicians of India

JF - Journal of Association of Physicians of India

SN - 0004-5772

IS - 3

ER -